Interpace Diagnostics (IDXG) Reports New York State Approval of ThyGenX for Indeterminate Thyroid Nodules
- Consumer staples stocks help Wall St. pare some losses
- BAT Reaches Deal to Acquire Reynolds American (RAI) for $49 Billion
- Verizon Communications (VZ) May Acquire Big Cable Company - NYP (CHTR) (CMCSA)
- Citron Research Negative on Lannett (LCI); Sees Shares at 'Zero' Over Long Term
- Einhorn's Greenlight Mentions Caterpillar (CAT) Short in Q4 Letter; Doesn't See Disney (DIS) Buying Netflix (NFLX)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Interpace Diagnostics Corp. (NASDAQ: IDXG), a company that provides specialized molecular diagnostic tests and pathology services, announced today that the New York State Department of Health has reviewed and approved for marketing ThyGenX™, the Company's NextGen Sequencing oncogene panel for indeterminate thyroid nodules.
The New York State approval of ThyGenX, which determines whether or not specific biomarkers are present, enables Interpace to market both ThyGenX and ThyraMir together in the state. ThyGenX typically precedes the running of ThyraMir, and they typically go hand in hand with 82% of ThyGenX cases warranting reflex to a more sophisticated, micro RNA assessment via ThyraMir.
According to Thyroid Disease Manager, New York State accounts for approximately 5% of the 600,000 Thyroid FNA biopsies performed in the US annually. Of the several states that require special licensure to provide testing to patients who reside in their jurisdiction, New York was the final state to issue approval.
The Company first launched ThyraMIR in New York State, which holds laboratory companies to some of the highest standards, in April 2015. Approval of ThyGenX was originally filed in 2015 after it was transferred to a NextGen Sequencing platform and an important PIK3CA biomarker was added.
Since November 2014 the Company has conducted over 6,000 combination ThyGenX/ThyraMir tests for over 400 physicians and hospitals outside of New York State.
Jack Stover, President and CEO of Interpace Diagnostics, commented, "We are pleased with the New York State acceptance of our data submission for ThyGenX and are prepared to leverage this opportunity right away. The ability to now market our combination test on a national basis represents a significant milestone for our Thyroid franchise and Company overall."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Interpace Diagnostics (IDXG) Announces Compliance with NASDAQ Minimum Bid Price Listing Requirement
- Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
- Eli Lilly & Co. (LLY), Incyte (INCY) Announce FDA Extends Review Period for Baricitinib
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!